Publications by authors named "P Galle"

Claim this Profile
L
Lenvatinib sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, Ciro Celsa, Claudia A M Fulgenzi, Peter R Galle

JHEP Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurofilament Light Chains in Serum Predict Post-Transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy.
Christian Labenz, Eva Maria Schleicher, Myriam Meineck, Martin A Kabelitz, Alena F Ehrenbauer, Peter Robert Galle

MedComm (2020)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Anthony B El-Khoueiry, Richard D Kim, William P Harris, Max W Sung, Dirk Waldschmidt, Peter R Galle

Hepatology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW - Authors' reply.
Peter R Galle, Thomas Yau, Thomas Decaens

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update.
Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega, Peter R Galle

J Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis